Further, when tumor samples were stratified according to melanoma subtype (i.e., cutaneous, occult, acral or mucosal), tumor mutation burden did not predict response to anti-PD-1 based immune checkpoint therapies66. This evidence concerns the gene PDCD1 and neoplasm.